SK144099A3 - Alkyl, alkenyl and alkynyl chrysamine g derivatives for the antemortem diagnosis of alzheimer's disease and i(in vivo) imaging and prevention of amyloid deposition - Google Patents

Alkyl, alkenyl and alkynyl chrysamine g derivatives for the antemortem diagnosis of alzheimer's disease and i(in vivo) imaging and prevention of amyloid deposition Download PDF

Info

Publication number
SK144099A3
SK144099A3 SK1440-99A SK144099A SK144099A3 SK 144099 A3 SK144099 A3 SK 144099A3 SK 144099 A SK144099 A SK 144099A SK 144099 A3 SK144099 A3 SK 144099A3
Authority
SK
Slovakia
Prior art keywords
group
chrysamine
lower alkyl
amyloid
independently
Prior art date
Application number
SK1440-99A
Other languages
English (en)
Slovak (sk)
Inventor
William E Klunk
Jay W Pettegrew
Chester A Mathis Jr
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Publication of SK144099A3 publication Critical patent/SK144099A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/66—Polycyclic acids with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/14—Styryl dyes
    • C09B23/141—Bis styryl dyes containing two radicals C6H5-CH=CH-
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
SK1440-99A 1997-04-18 1998-04-20 Alkyl, alkenyl and alkynyl chrysamine g derivatives for the antemortem diagnosis of alzheimer's disease and i(in vivo) imaging and prevention of amyloid deposition SK144099A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/837,494 US6168776B1 (en) 1994-07-19 1997-04-18 Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
PCT/US1998/007889 WO1998047969A1 (en) 1997-04-18 1998-04-20 Alkyl, alkenyl and alkynyl chrysamine g derivatives for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition

Publications (1)

Publication Number Publication Date
SK144099A3 true SK144099A3 (en) 2000-07-11

Family

ID=25274617

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1440-99A SK144099A3 (en) 1997-04-18 1998-04-20 Alkyl, alkenyl and alkynyl chrysamine g derivatives for the antemortem diagnosis of alzheimer's disease and i(in vivo) imaging and prevention of amyloid deposition

Country Status (19)

Country Link
US (3) US6168776B1 (pt)
EP (1) EP0977815A1 (pt)
JP (1) JP2002500634A (pt)
KR (1) KR20010006552A (pt)
CN (1) CN1261906A (pt)
AR (1) AR012845A1 (pt)
AU (1) AU7136998A (pt)
BR (1) BR9809580A (pt)
CA (1) CA2286607A1 (pt)
EE (1) EE9900503A (pt)
HU (1) HUP0003804A3 (pt)
IL (1) IL132426A0 (pt)
NO (1) NO995088L (pt)
NZ (1) NZ500714A (pt)
PL (1) PL336321A1 (pt)
SK (1) SK144099A3 (pt)
TR (1) TR199903115T2 (pt)
WO (1) WO1998047969A1 (pt)
ZA (1) ZA983301B (pt)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417178B1 (en) * 1994-07-19 2002-07-09 University Of Pittsburgh Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
BR0016652A (pt) * 1999-12-23 2002-11-19 Neurochem Inc Métodos para inibir angiopatia amilóide cerebral, para tratar um estado de doença caracterizado por angiopatia amilóide cerebral em um indivìduo, e para diagnosticar angiopatia amilóide cerebral em um indivìduo
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
EP2151187A1 (en) * 2000-08-21 2010-02-10 The General Hospital Corporation Methods for diagnosing a neurodegenerative condition
US7297326B2 (en) * 2000-08-21 2007-11-20 The General Hospital Corporation Ocular diagnosis of Alzheimer's disease
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
HU230375B1 (hu) 2000-08-24 2016-03-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Tioflavin-származékok és alkalmazásuk az Alzheimer-kór diagnózisában és kezelésében
US6589504B1 (en) 2000-09-22 2003-07-08 Pharmacia & Upjohn Company Compounds and methods for diagnosing and treating amyloid-related conditions
US7668586B2 (en) * 2000-11-02 2010-02-23 Cornell Research Foundation, Inc. In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease
US6379650B1 (en) 2001-03-19 2002-04-30 Wesley Scott Ashton Technetium 99m-N2S2-congo red complexes utilizing diamide dithiolate ligand systems for radioimaging
CN100422180C (zh) 2001-04-23 2008-10-01 宾夕法尼亚州大学理事会 淀粉样斑块聚集抑制剂和诊断成像剂
EP1420830B1 (en) * 2001-04-27 2011-03-09 The General Hospital Corporation Ocular diagnosis of alzheimer's disease
US20030211459A1 (en) * 2001-10-25 2003-11-13 The General Hospital Corporation Drug development by rapid neuroimaging of neural cells
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US7407778B2 (en) 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
NZ536054A (en) * 2002-04-09 2009-10-30 Scripps Research Inst Motif-grafted hybrid polypeptides and uses thereof
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
TW200413009A (en) * 2002-10-04 2004-08-01 Univ Pennsylvania Biphenyls and fluorenes as imaging agents in alzheimer's disease
US7692011B2 (en) 2002-10-04 2010-04-06 Prana Biotechnology Limited 8-hydroxy and 8-mercapto quinazolinones
JP2006515999A (ja) 2002-11-14 2006-06-15 ブレインズゲート リミティド 刺激のための外科用ツール及び技法
US20040204344A1 (en) * 2003-01-22 2004-10-14 Xudong Huang Amyloid-binding, metal-chelating agents
GB0307855D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
EP1631561B1 (en) 2003-05-07 2010-08-18 General Electric Company Compositions and methods for non-invasive imaging of soluble beta-amyloid
US20040223912A1 (en) * 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
JP2007504283A (ja) * 2003-05-20 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア β−アミロイド斑に作用物質を結合させる方法
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
WO2004110963A2 (en) * 2003-05-29 2004-12-23 Pettegrew Jay W Glycerophosphocholine and its derivatives for medical imaging neuropsychiatric disorders
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
US20050214222A1 (en) * 2004-02-13 2005-09-29 Mckinnon Stuart J In vivo imaging of amyloid plaques in glaucoma using intravenous injectable dyes
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
GB0405193D0 (en) * 2004-03-08 2004-04-21 Medical Res Council Compounds
WO2006045096A2 (en) * 2004-10-20 2006-04-27 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
EP1893245A4 (en) * 2005-06-24 2009-06-24 Univ Pennsylvania RADIOACTIVELY MARKED PEGYLATION OF LIGANDS FOR USE AS A CONTRAST
NZ566180A (en) * 2005-07-29 2011-04-29 Resverlogix Corp Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
WO2007047815A2 (en) * 2005-10-18 2007-04-26 The Brigham And Women's Hospital, Inc. Diagnosis of transmissible spongiform encephalopathy
US20090142269A1 (en) * 2005-12-01 2009-06-04 University Of Oittsburgh-Of The Commonwealth System Of Higher Education Isotoypically-labeled benzothiazole compounds as imaging agents for amyloidogenic proteins
JP5170783B2 (ja) 2006-04-11 2013-03-27 コグノプティックス， インコーポレイテッド 眼の画像化
DK2012789T3 (da) 2006-04-14 2013-12-16 Prana Biotechnology Ltd Fremgangsmåde til behandling af aldersrelateret makulær degeneration (AMD)
WO2008118122A2 (en) * 2006-05-08 2008-10-02 Molecular Neuroimaging, Llc Compounds and amyloid probes thereof for therapeutic and imaging uses
WO2007139777A2 (en) * 2006-05-26 2007-12-06 Merck & Co., Inc. Methods for the diagnosis and prognosis of alzheimer's disease using csf protein profiling
US7745222B2 (en) * 2006-10-13 2010-06-29 General Electric Company Amyloid binding assays
US7858663B1 (en) * 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
US7910579B2 (en) 2006-12-25 2011-03-22 Tohoku University Benzoxazole derivatives
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
WO2008144065A1 (en) * 2007-05-21 2008-11-27 Neuroptix Corporation Ophthalmic formulations of amyloid- contrast agents and methods of use thereof
JP5172229B2 (ja) * 2007-07-04 2013-03-27 住友化学株式会社 アゾ化合物又はその塩
EP2198040B1 (en) * 2007-08-31 2018-08-15 Case Western Reserve University In vivo imaging of myelin
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
CA2978149C (en) 2008-03-21 2019-02-12 The General Hospital Corporation Inositol derivatives for the detection and treatment of alzheimer's disease and related disorders
BRPI0910550A2 (pt) * 2008-04-30 2015-09-29 Novartis Ag ensaio para confôrmeros patogênicos
WO2009146388A1 (en) 2008-05-28 2009-12-03 The Trustees Of Columbia University In The City Of New York Voxel-based methods for assessing subjects using positron emission tomography
CA2711103C (en) 2008-06-26 2016-08-09 Resverlogix Corp. Methods of preparing quinazolinone derivatives
WO2010079431A2 (en) 2009-01-08 2010-07-15 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2408454A2 (en) 2009-03-18 2012-01-25 Resverlogix Corp. Novel anti-inflammatory agents
CU23844B1 (es) 2009-04-17 2012-10-15 Ct De Neurociencias De Cuba Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
KR101892987B1 (ko) 2009-04-22 2018-08-30 리스버로직스 코퍼레이션 신규한 소염제
US8455836B2 (en) * 2009-10-28 2013-06-04 Roy Stockdale Sensor system for constantly monitoring an irradiance level of a UV lamp and for being operated by power from a sensor thereof
US9555130B2 (en) * 2010-02-25 2017-01-31 Case Western Reserve University Compositions and methods for in vivo imaging of myelin in the peripheral nervous system
MX357628B (es) 2010-08-16 2018-07-17 Cognoptix Inc Star Sistema y metodo para detectar proteinas amiloides.
JP5992049B2 (ja) 2011-11-01 2016-09-14 レスバーロジックス コーポレイション 置換されたキナゾリノンのための経口速放性製剤
JP6499077B2 (ja) 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
CU20130027A7 (es) 2013-02-28 2014-10-30 Ct De Neurociencias De Cuba Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
JP2016534063A (ja) 2013-10-22 2016-11-04 ザ ジェネラル ホスピタル コーポレイション クロモリン誘導体ならびに関連するイメージングおよび治療方法
AR098232A1 (es) 2013-10-31 2016-05-18 Cognoptix Inc Métodos de preparación de una formulación oftálmica y usos de la misma
EP2878335B1 (en) 2013-11-10 2018-01-03 Brainsgate Ltd. Implant and delivery system for neural stimulator
CN107530356A (zh) 2015-03-13 2018-01-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
KR101943706B1 (ko) * 2016-08-25 2019-01-29 성균관대학교산학협력단 유비퀴틴 활성 저해용 조성물
CN109922800B (zh) 2016-08-31 2023-06-13 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
AU2017423862A1 (en) 2017-07-20 2020-02-06 Aztherapies, Inc. Powdered formulations of cromolyn sodium and ibuprofen
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US329638A (en) 1885-11-03 Fabriken
US394841A (en) 1888-12-18 Carl duisberg
US401024A (en) 1889-04-09 Benfabriken
US622961A (en) 1899-04-11 Ivan levinstein and carl mensching
US1979534A (en) 1931-10-15 1934-11-06 Farastan Company Disazo compound for therapeutic use
CH554848A (de) 1967-10-03 1974-10-15 Ciba Geigy Ag Verfahren zur herstellung neuer stilben-derivate.
CH566420B5 (en) 1967-10-03 1975-09-15 Ciba Geigy Ag Bis-stilbene compds for use as optical brighteners
CH547243A (de) 1970-07-23 1974-03-29 Ciba Geigy Ag Verfahren zur herstellung von styrylverbindungen.
DE2039993A1 (de) 1970-08-12 1972-02-17 Basf Ag Optische Aufheller der Bisstyrylbenzolreihe
US4016156A (en) 1972-06-30 1977-04-05 Ciba-Geigy Corporation Distyryl compounds
CH574950A5 (pt) 1972-06-30 1976-04-30 Ciba Geigy Ag
DE2364396A1 (de) 1973-12-22 1975-07-10 Basf Ag Neue bisstyrylarylverbindungen
LU75628A1 (pt) 1976-08-19 1978-04-13
US5008099A (en) 1987-04-08 1991-04-16 Salutar, Inc. Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor
US5039511A (en) 1987-04-08 1991-08-13 Salutar, Inc. Amyloidosis and alzheimer's disease diagnostic assay and reagents therefor
US4933156A (en) 1987-04-08 1990-06-12 Salutar, Inc. Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor
AU620327B2 (en) 1987-04-08 1992-02-20 Salutar, Inc. Amyloidosis and alzheimer's disease diagnostic assay and reagents therefor
US5231000A (en) 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
JP2641529B2 (ja) * 1988-10-26 1997-08-13 三菱化学株式会社 新規有機高分子
WO1992016239A1 (en) 1991-03-13 1992-10-01 The Regents Of The University Of Minnesota Radiopharmaceutical agents for the detection of alzheimer's disease
US5297562A (en) 1991-04-01 1994-03-29 President And Fellows Of Harvard College Method for detecting and treating Alzheimer's disease
US5434050A (en) 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5276059A (en) 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
EP1110945A3 (en) 1995-05-01 2003-05-07 University Of Pittsburgh Azocompounds for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition

Also Published As

Publication number Publication date
MX9909557A (es) 2002-12-13
US6114175A (en) 2000-09-05
TR199903115T2 (xx) 2000-05-22
EP0977815A1 (en) 2000-02-09
EE9900503A (et) 2000-06-15
AU7136998A (en) 1998-11-13
CA2286607A1 (en) 1998-10-29
NO995088L (no) 1999-12-17
HUP0003804A3 (en) 2002-09-30
AR012845A1 (es) 2000-11-22
JP2002500634A (ja) 2002-01-08
IL132426A0 (en) 2001-03-19
NO995088D0 (no) 1999-10-18
PL336321A1 (en) 2000-06-19
HUP0003804A2 (hu) 2001-06-28
US6168776B1 (en) 2001-01-02
KR20010006552A (ko) 2001-01-26
US6133259A (en) 2000-10-17
WO1998047969A1 (en) 1998-10-29
ZA983301B (en) 1999-10-20
NZ500714A (en) 2001-09-28
CN1261906A (zh) 2000-08-02
BR9809580A (pt) 2001-06-19

Similar Documents

Publication Publication Date Title
SK144099A3 (en) Alkyl, alkenyl and alkynyl chrysamine g derivatives for the antemortem diagnosis of alzheimer's disease and i(in vivo) imaging and prevention of amyloid deposition
US6417178B1 (en) Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
US7351401B2 (en) Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition
AU2001286702A1 (en) Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease
AU712552B2 (en) Azo compounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
CZ370099A3 (cs) Alkylové, alkenylové a alkinylové deriváty chrysaminu G pro diagnostiku Alzheimerovy nemoci a in vivo zobrazení a prevenci deposit amyloidu
CZ20001685A3 (cs) Sloučeniny pro diagnózu Alzheimerovy nemoci a in vivo zobrazení a prevenci deposit amyloidu
MXPA99009557A (en) Alkyl, alkenyl and alkynyl chrysamine g derivatives for the antemortem diagnosis of alzheimer's disease and (in vivo) imaging and prevention
MXPA00004371A (en) Compounds for the antemortem diagnosis of alzheimer's disease and i(in vivo) imaging and prevention of amyloid deposition